Metal-based antitumor compounds: beyond cisplatin
MetadataShow full item record
Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells.
Showing items related by title, author, creator and subject.
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study Global Burden of Disease Cancer CollaborationFitzmaurice, C.; Allen, C.; Barber, R.; Barregard, L.; Bhutta, Z.; Brenner, H.; Dicker, D.; Chimed-Orchir, O.; Dandona, R.; Dandona, L.; Fleming, T.; Forouzanfar, M.; Hancock, J.; Hay, R.; Hunter-Merrill, R.; Huynh, C.; Hosgood, H.; Johnson, C.; Jonas, J.; Khubchandani, J.; Kumar, G.; Kutz, M.; Lan, Q.; Larson, H.; Liang, X.; Lim, S.; Lopez, A.; MacIntyre, M.; Marczak, L.; Marquez, N.; Mokdad, A.; Pinho, C.; Pourmalek, F.; Salomon, J.; Sanabria, J.; Sandar, L.; Sartorius, B.; Schwartz, S.; Shackelford, K.; Shibuya, K.; Stanaway, J.; Steiner, C.; Sun, J.; Takahashi, K.; Vollset, S.; Vos, T.; Wagner, J.; Wang, H.; Westerman, R.; Zeeb, H.; Zoeckler, L.; Abd-Allah, F.; Ahmed, M.; Alabed, S.; Alam, N.; Aldhahri, S.; Alem, G.; Alemayohu, M.; Ali, R.; Al-Raddadi, R.; Amare, A.; Amoako, Y.; Artaman, A.; Asayesh, H.; Atnafu, N.; Awasthi, A.; Saleem, H.; Barac, A.; Bedi, N.; Bensenor, I.; Berhane, A.; Bernabé, E.; Betsu, B.; Binagwaho, A.; Boneya, D.; Campos-Nonato, I.; Castañeda-Orjuela, C.; Catalá-López, F.; Chiang, P.; Chibueze, C.; Chitheer, A.; Choi, J.; Cowie, B.; Damtew, S.; Das Neves, J.; Dey, S.; Dharmaratne, S.; Dhillon, P.; Ding, E.; Driscoll, T.; Ekwueme, D.; Endries, A.; Farvid, M.; Farzadfar, F.; Fernandes, J.; Miller, Ted (2017)Importance: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. Objective: To estimate mortality, incidence, years lived with disability ...
Rates of colonoscopy in the 3 years prior to a diagnosis of colorectal cancer in Western Australia: assessment of risk factors for missed and interval cancers. Preliminary results from a population-based studySalama, M.; Harma, C.; Fritschi, Lin; Heyworth, J.; Raftopoulos, S.; Ee, H. (2014)Introduction and Aims: Colonoscopy is the gold standard for diagnosing colorectal cancer (CRC) however there is a miss rate for cancers of up to 7.9%, with significant variability in this figure from different populations ...
Incorporating competing risk theory into evaluations of changes in cancer survival: making the most of cause of death and routinely linked sociodemographic dataWright, Cameron ; Nowak, Anna; Halkett, Georgia ; Moorin, Rachael (2020)BACKGROUND: Relative survival is the most common method used for measuring survival from population-based registries. However, the relative survival concept of 'survival as far as the cancer is concerned' can be biased ...